Tecovirimat

• CAT Number: I037080
• CAS Number: 869572-92-9
• Molecular Formula: C19H15F3N2O3
• Molecular Weight: 376.33
• Purity: 98%
• Synonyms: N-[(1S,2S,6R,7R,8R,10S)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide
• Target: VARV p37
• Target Protein: P33815
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: IC50: 10 nM
• InChI: InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)/t10-,11+,12+,13-,14-,15+
• InChIKey: CSKDFZIMJXRJGH-VWLPUNTISA-N
• SMILES: C1[C@@H]2[C@H]1[C@@H]3C=C[C@H]2[C@@H]4[C@H]3C(=O)N(C4=O)NC(=O)C5=CC=C(C=C5)C(F)(F)F

Tecovirimat（Cat No.:I037080）is an antiviral medication approved for the treatment of smallpox and related orthopoxvirus infections, such as monkeypox and cowpox. It works by inhibiting the viral VP37 envelope protein, which is essential for the formation and spread of virus particles within the body. By blocking this protein, Tecovirimat prevents the virus from leaving infected cells, limiting its ability to spread. Tecovirimat offers a vital defense against orthopoxvirus outbreaks, especially in the event of bioterrorism or resurgence, providing an effective and well-tolerated treatment option for smallpox and related diseases.

Reference

[1]. Yang G, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol. 2005 Oct;79(20):13139-49.
[Content Brief]

[2]. Quenelle DC, et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother. 2007 Feb;51(2):689-95.
[Content Brief]

[3]. Andrew T Russo, et al. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther. 2021 Mar;19(3):331-344.
[Content Brief]